OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Rheumatic Diseases in Older Adults
Submission Deadline: March 01, 2022 (Open) Submit Now
Rossana Scrivo, MD, PhD
Unit of Rheumatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy
Tel: +39 06 49974699
Research Interests: Rheumatic diseases; autoimmunity; inflammation; TNF; autoimmune disorders; autoantibodies; immunology of infectious diseases; inflammatory diseases
About This Topic
We are pleased to announce the special issue titled “Rheumatic Diseases in Older Adults" to be developed in the next few months. Rheumatic diseases cause an enormous global burden, which is dramatically increasing worldwide, particularly due to aging populations. In the elderly, rheumatic diseases cover the spectrum of those conditions affecting all age groups to those that are seen more often in the aging population. Most patients with chronic rheumatic diseases experience reduced work capacity and deteriorating quality of life. These outcomes may be even more severe in older adults because of limiting physical and mental capacities and functional ability. Furthermore, premature mortality, often due to an increased risk of developing cardiovascular disease, has been documented in several rheumatic diseases, including osteoarthritis, gout, vasculitis, and others, that largely affect older people. The focus of this special issue on rheumatic diseases in the elderly will hopefully contribute to raising awareness of these issues beyond the rheumatology community.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.